Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
We hypothesized that to reduce the adverse effects of intravitreal bevacizumab on ocular
tissue and whole body, intravitreal injection of a low concentration of bevacizumab and
conducting vitrectomy shortly after the injection is useful. In the present prospective,
double-masked, randomized, controlled study, we aimed to verify the usefulness of
intravitreal injection of 0.16 mg/0.05 ml bevacizumab one day before conducting vitrectomy
for PDR.